Liu Jia, Huang Hong-Yun
Beijing Hongtianji Neuroscience Academy, Beijing 100041, China.
Neurosci Bull. 2007 Nov;23(6):377-82. doi: 10.1007/s12264-007-0056-4.
It has been extensively confirmed that fetal ventral mesencephalic cell (VMC) transplantation can ameliorate the symptoms of Parkinson's disease (PD). But there are still several problems to be resolved before the extensive clinical application of this technology. The major limitations are the poor survival of grafted dopamine (DA) neurons and restricted dopaminergic reinnervation of host striatum. Some attempts have been made to solve these problems including use of some trophic factor and co-transplantation with neural/paraneural origins. The purpose of this review is to overview advances of the means improving the survival of grafts and their current limitations.
胎儿腹侧中脑细胞（VMC）移植可改善帕金森病（PD）症状，这已得到广泛证实。但在该技术广泛应用于临床之前，仍有几个问题有待解决。主要限制是移植的多巴胺（DA）神经元存活率低以及宿主纹状体多巴胺能神经再支配受限。人们已尝试采取一些措施来解决这些问题，包括使用某些神经营养因子以及与神经/神经旁起源组织共同移植。本综述的目的是概述提高移植物存活率方法的进展及其当前局限性。
